Dietary Supplements and Middle Aged Women (Creatine)
NCT07729930, Not applicable, Recruiting, Loughborough University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Dietary Supplements and Middle Aged Women (Creatine) | ClinicalTrials.gov |
| NCT number | NCT07729930 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 38 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Loughborough University | ClinicalTrials.gov |
| Conditions | Cognition, Muscle Strength, Fatigue Symptom, Blood Pressure and Augmentation Index, Body Composition Changes, Sleep, Gastrointestinal Comfort, Quality of Life, Joint Pain, Inflammation Biomarkers, Bone Metabolism Biomarkers, Menopause Symptoms | ClinicalTrials.gov |
| Interventions | Creatine Monohydrate, Placebo control | ClinicalTrials.gov |
| First posted | 2026-07-28 | ClinicalTrials.gov |
| Last updated | 2026-07-28 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Cognitive function | 8 weeks | Participants will complete 3 cognitive function tests on a laptop in a quiet room: the Letter Comparison test (measuring reaction time (ms) and accuracy (%)), the Backwards Digit Span test (measuring the longest correct span score), and the Stroop Colour Word test (measuring congruent/incongruent/neutral reaction time (ms) and accuracy (%), and the Interference Effect (calculated as incongruent reaction time - congruent reaction time). | ClinicalTrials.gov |
| Secondary | Body composition measured using bioelectrical impedance analysis (BIA) | 8 weeks | The following body composition measures will be taken: body mass (kg), fat mass (kg), calculated fat percentage (%), fat free mass (kg), body mass index (kg/m2, calculated as body mass divided by height squared), total body water (L), calculated total body water percentage | ClinicalTrials.gov |
| Secondary | Hand grip strength dynamometry (kg) | 8 weeks | Hand grip strength will be assessed following the Southampton Protocol (Roberts et al., 2011), where 3 measures will be taken for each hand. | ClinicalTrials.gov |
| Secondary | Blood pressure (mmHg) | 8 weeks | After 10 minutes of seated rest, 3 blood pressure readings will be taken and recorded using an automated cuff. | ClinicalTrials.gov |
| Secondary | Augmentation index | 8 weeks | Augmentation index will be assessed using radial artery tonometry. Aortic Augmentation (AP, mmHg) and Aortic Augmentation Index (AP/PP, %) will be recorded. | ClinicalTrials.gov |
| Secondary | Fatigue under 2 conditions measured by a 100 mm visual analogue scale (VAS) | 8 weeks | Participants will place a vertical line on the scale (ranging from no fatigue at all (0 mm) to extremely fatigued (100 mm)) which will be measured and recorded. Participants will complete a visual analogue scale for 2 conditions: right now, and during daily activities in the last week (such as walking, getting up from chairs, exercising). | ClinicalTrials.gov |
| Secondary | Sleep quality measured by Athens Insomnia Scale and a simple Sleep Quality Scale | 8 weeks | The Athens Insomnia Scale is an 8-point questionnaire where participants rank different aspects of their sleep (sleep induction, awakenings during the night, final awakening, total sleep duration, overall sleep quality, sense of wellbeing during the day, functioning during the day, and sleepiness during the day) provided that it occurred at least 3 times in the last week from 0 (no issue) to 3 (serious issue). A lower total score indicates better sleep. | ClinicalTrials.gov |
| Secondary | Quality of life assessed by the 36-Item Short Form Survey Instrument (SF-36) | 8 weeks | A total score will be calculated, with a higher score indicating a better quality of life | ClinicalTrials.gov |
| Secondary | Gastrointestinal comfort measure via a Likert Scale under 3 conditions | 8 weeks | Participants select one option on the Likert scale ranging from 1 (no GI discomfort) to 4 (lots/frequent/extreme GI discomfort). There is a Likert Scale for each of the following conditions: GI discomfort right now, GI discomfort frequency in the last 8 weeks, and GI discomfort severity in the last 8 weeks. | ClinicalTrials.gov |
| Secondary | Menstrual cycle/menopause symptom questionnaire | 8 weeks | The questionnaire assesses 12 common menstrual cycle/menopause symptoms. Participants rate the severity (0 = none, to 3 = severe) and frequency (0 = never, to 3 = often) of these symptoms. A higher score indicates worse menstrual cycle/menopause symptoms | ClinicalTrials.gov |
| Secondary | Joint pain assessed via a 100mm visual analogue scale (VAS) | 8 weeks | Participants will place a vertical line on the scale (ranging from no pain (0 mm) to unbearable pain (100 mm)) which will be measured and recorded. Participants will complete a visual analogue scale for 3 conditions: after standing rest, after 5 body weight squats, and in response to pain levels during daily activities in the last week (such as walking, getting up from chairs, exercising). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Primary outcome | ConductCognition |
| Pattern and Letter Comparison | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)